UMADT participated in Sambutan Hari Kanser Sedunia 2026 on 4 February 2026 at Wisma DBP, Kuala Lumpur. UMADT’s information booth highlighted ongoing investigator-led clinical trials under the IA-DATA Alliance, including the NeART-M and NeART-CIN studies on drug repurposing for cancer care, and provided insights on public engagement and cancer awareness.
Nearly half of the world’s population still lacks access to basic diagnostic tests, while life saving cancer treatments remain unaffordable for many. In her article, Prof Ivy highlights how the Universiti Malaya Affordable Diagnostics & Therapeutics initiative is working to bridge science, access, and equity by developing affordable diagnostics and repurposed treatments designed for real world impact in Malaysia and the ASEAN region.
This Impact Report documents a year-long effort to examine why access to effective dengue diagnostics remains limited in endemic countries, despite the availability of scientific knowledge and diagnostic technologies.
IA-DATA provided a progress update to the Minister of Health Malaysia on 2025 exemplar projects, aligned with national health reforms and focused on equitable access to diagnostics and therapeutics for Malaysia, ASEAN, and the Global South.
The International Affordable Diagnostics & Therapeutics Alliance (IA-DATA) continues to strengthen its collaborative footprint in Malaysia through ongoing discussions to support the establishment of The Global Health Network Malaysia.
A recent article published by The Star has highlighted the outcomes and significance of the Drug Repurposing Roundtable held in October, showcasing Malaysia’s growing leadership in developing affordable treatments for cancers and rare diseases.
UMADT was pleased to participate in a session held as part of the Healthcare Trade Mission to Malaysia, led by the UK in Malaysia (British High Commission) and Healthcare UK.
As part of its ongoing international collaborations, Universiti Malaya Affordable Diagnostics and Therapeutics (UMADT) undertook a visit to its collaborator, City St George’s, University of London, focused on scientist training, technology transfer, and innovation partnerships.
Dr Nithya Balasundaram and Prof Vikram Mathews and their team from Christian Medical College, Vellore published in Nature’s Cell Death & Disease that introduces a new approach to exploiting metabolic dependencies in acute myeloid leukemia (AML). A strong example of how to take drug repurposing for haematological malignancies from bench to bedside .
This MoU officially establishes Mediven as an industry partner of the SSDxA, strengthening the Alliance’s growing ecosystem of collaborators.